Radiosynthesis and preclinical evaluation of a
68Ga
Bifunctional chelator (BFC)
CXCR4 receptor
Glioblastoma (GBM)
PET tracer
Positron emission tomography
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
07
06
2024
accepted:
30
07
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
This study aimed to develop a novel positron emission tomography (PET) tracer, [ A bifunctional chelator was prepared by conjugating the amine group of TIQ15 with p-NCS-Bz-DOTA, yielding TD-01, with a high yield (68.92%). TD-01 was then radiolabeled with [ The newly developed CXCR4 PET tracer, [
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to develop a novel positron emission tomography (PET) tracer, [
METHODS
METHODS
A bifunctional chelator was prepared by conjugating the amine group of TIQ15 with p-NCS-Bz-DOTA, yielding TD-01, with a high yield (68.92%). TD-01 was then radiolabeled with
RESULTS
RESULTS
[
CONCLUSION
CONCLUSIONS
The newly developed CXCR4 PET tracer, [
Identifiants
pubmed: 39162901
doi: 10.1186/s41181-024-00290-y
pii: 10.1186/s41181-024-00290-y
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61Subventions
Organisme : National Research Council of Thailand
ID : The National Research Council of Thailand (NRCT) under Molecular Probes for Imaging International Research Network (IRN N10A650046) (O.V.)
Organisme : Graduate School, Chulalongkorn University
ID : 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship
Organisme : Graduate School, Chulalongkorn University
ID : 90th Anniversary of Chulalongkorn University Scholarship (GCUGR1125652013D)
Organisme : Trond Mohn Foundation (TMF) and Helse-Nord grant
ID : Trond Mohn Foundation (TMF)
Organisme : Trond Mohn Foundation (TMF) and Helse-Nord grant
ID : Helse-Nord grant HNF1591-21/HNF1695-23
Informations de copyright
© 2024. The Author(s).
Références
Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. 2020;11:2109. https://doi.org/10.3389/fimmu.2020.02109 .
doi: 10.3389/fimmu.2020.02109
pubmed: 32983169
pmcid: 7484992
Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA. 1997;94:1925–30. https://doi.org/10.1073/pnas.94.5.1925 .
doi: 10.1073/pnas.94.5.1925
pubmed: 9050881
pmcid: 20019
Borja AJ, Hancin EC, Raynor WY, Ayubcha C, Detchou DK, et al. A critical review of PET tracers used for brain tumor imaging. PET Clin. 2021;16(2):219–31. https://doi.org/10.1016/j.cpet.2020.12.004 .
doi: 10.1016/j.cpet.2020.12.004
pubmed: 33589386
Chatterjee S, Azad BB, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82. https://doi.org/10.1016/B978-0-12-411638-2.00002-1 .
doi: 10.1016/B978-0-12-411638-2.00002-1
pubmed: 25287686
pmcid: 4322894
ClinicalTrials.gov [Internet]. Pentixapharm AG: National Library of Medicine (US). Identifier NCT06125028, [
ClinicalTrials.gov [Internet]. Nantes University Hospital: National Library of Medicine (US). Identifier NCT06356922, Study Assessing RLT Using [
Dreher N, Hahner S, Fuß CT, Schlötelburg W, Hartrampf PE, et al. CXCR4-directed PET/CT with [
doi: 10.1007/s00259-023-06547-z
pubmed: 38082196
Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin EC, et al. Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer. Front Immunol. 2018;9:3018. https://doi.org/10.3389/fimmu.2018.03018 .
doi: 10.3389/fimmu.2018.03018
pubmed: 30622535
pmcid: 6308162
Elboga U, Sahin S, Cayirli YB, Okuyan M, Aktas G, et al. Comparison of [
doi: 10.3390/tomography8010024
pubmed: 35202189
pmcid: 8875266
Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol. 2006;72(5):588–96. https://doi.org/10.1016/j.bcp.2006.05.010 .
doi: 10.1016/j.bcp.2006.05.010
pubmed: 16815309
Goffart N, Kroonen J, Valentin ED, Dedobbeleer M, Denne A, et al. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. Neuro Oncol. 2015;17(1):81–94. https://doi.org/10.1093/neuonc/nou144 .
doi: 10.1093/neuonc/nou144
pubmed: 25085362
Haege S, Einer C, Thiele S, Mueller W, Nietzsche S, et al. CXC chemokine receptor 7 (CXCR7) regulates CXCR4 protein expression and capillary tuft development in mouse kidney. PLoS ONE. 2012;7(8): e42814. https://doi.org/10.1371/journal.pone.0042814 .
doi: 10.1371/journal.pone.0042814
pubmed: 22880115
pmcid: 3412803
Herholz K, Langen KJ, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med. 2012;42(6):356–70. https://doi.org/10.1053/j.semnuclmed.2012.06.001 .
doi: 10.1053/j.semnuclmed.2012.06.001
pubmed: 23026359
pmcid: 3925448
Holzgreve A, Biczok A, Ruf VC, Liesche-Starnecker F, Steiger K, et al. PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging. Front Oncol. 2021;11: 646387. https://doi.org/10.3389/fonc.2021.646387 .
doi: 10.3389/fonc.2021.646387
pubmed: 33859946
pmcid: 8042319
Hout AV, D’huys T, Oeyen M, Schols D, Loy TM. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS ONE. 2017;12(4): e0176057. https://doi.org/10.1371/journal.pone.0176057 .
doi: 10.1371/journal.pone.0176057
pubmed: 28410420
pmcid: 5391968
Jacobs SM, Wesseling P, Keizer B, Tolboom N, Ververs T, et al. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
doi: 10.1007/s00259-021-05196-4
pubmed: 33550492
Jaffar J, Griffiths K, Oveissi S, Duan M, Foley M. CXCR4
doi: 10.1186/s12931-020-01467-0
pubmed: 32843095
pmcid: 7449054
Jenkinson S, Thomson M, McCoy D, Edelstein M, Danehower S, et al. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. Antimicrob Agents Chemother. 2010;54(2):817–24. https://doi.org/10.1128/aac.01293-09 .
doi: 10.1128/aac.01293-09
pubmed: 19949058
Jiang G, Zheng ZQ, Zhang J, Tian Z, Li X, et al. Development and validation of CXCR4 nomogram-based immune infiltration/tumor inflammation in primary glioblastoma. Brain Sci. 2023;13(8):1152. https://doi.org/10.3390/brainsci13081152 .
doi: 10.3390/brainsci13081152
pubmed: 37626511
pmcid: 10452349
Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694–705. https://doi.org/10.1172/jci40283 .
doi: 10.1172/jci40283
pubmed: 20179352
pmcid: 2827954
Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, et al. Delineation of brain tumor extent with [
doi: 10.1158/1078-0432.ccr-04-0262
pubmed: 15534088
Lee B, Sharron M, Montaner L, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA. 1999;96:5215–20. https://doi.org/10.1073/pnas.96.9.5215 .
doi: 10.1073/pnas.96.9.5215
pubmed: 10220446
pmcid: 21844
Lindberg A, Chassé M, Varlow C, Pees A, Vasdev N. Strategies for designing novel positron emission tomography (PET) radiotracers to cross the blood–brain barrier. J Labelled Comp Radiopharm. 2023;66(9):205–21. https://doi.org/10.1002/jlcr.40192 .
doi: 10.1002/jlcr.40192
pubmed: 36815704
Lindemann M, Oteiza A, Martin-Armas M, Guttormsen Y, Moldes-Anaya A, et al. Glioblastoma PET/MRI: kinetic investigation of [
doi: 10.1007/s00259-022-06040-z
pubmed: 36416908
Lith S, Pruis IJ, Tolboom N, Snijders TJ, Henssen D, et al. PET imaging and protein expression of prostate-specific membrane antigen in glioblastoma: a multicenter inventory study. J Nucl Med. 2023;64(10):1526–31. https://doi.org/10.2967/jnumed.123.265738 .
doi: 10.2967/jnumed.123.265738
pubmed: 37652540
Liu F, Qi L, Liu B, Liu J, Zhang H, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS ONE. 2015;10(3): e0116683. https://doi.org/10.1371/journal.pone.0116683 .
doi: 10.1371/journal.pone.0116683
pubmed: 25775399
pmcid: 4361589
Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, et al. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol. 2012;83(4):472–9. https://doi.org/10.1016/j.bcp.2011.11.020 .
doi: 10.1016/j.bcp.2011.11.020
pubmed: 22146583
Muthukumar S, Darden J, Crowley J, Witcher M, Kiser J. A comparison of PET tracers in recurrent high-grade gliomas: a systematic review. Int J Mol Sci. 2023;24(1):408. https://doi.org/10.3390/ijms24010408 .
doi: 10.3390/ijms24010408
Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, et al. An intra-individual comparison of MRI, [
doi: 10.1371/journal.pone.0095830
pubmed: 24759867
pmcid: 3997484
Nyunt MM, Becker S, MacFarland RT, Chee P, Scarborough R, et al. Pharmacokinetic effect of AMD070, an oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. JAIDS J Acquired Immune Defic Syndr. 2008;47(5):559–65. https://doi.org/10.1097/qai.0b013e3181627566 .
doi: 10.1097/qai.0b013e3181627566
Oum YH, Shetty D, Yoon Y, Liang Z, Voll RJ, et al. A benzenesulfonamide derivative as a novel PET radioligand for CXCR4. Bioorg Med Chem. 2020;28(2): 115240. https://doi.org/10.1016/j.bmc.2019.115240 .
doi: 10.1016/j.bmc.2019.115240
pubmed: 31843463
Poschenrieder A, Schottelius M, Schwaiger M, Wester HJ. Preclinical evaluation of [
doi: 10.1186/s13550-016-0227-2
pubmed: 27655427
pmcid: 5031577
Renard I, Domarkas J, Poty S, Burke BP, Roberts DP, et al. In vivo validation of
doi: 10.1016/j.nucmedbio.2023.108335
pubmed: 37068392
Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100(23):13513–8. https://doi.org/10.1073/pnas.2235846100 .
doi: 10.1073/pnas.2235846100
pubmed: 14595012
pmcid: 263845
Schoofs G, Hout AV, D’huys T, Schols D, Loy TV, et al. A flow cytometry-based assay to identify compounds that disrupt binding of fluorescently-labeled CXC chemokine ligand 12 to CXC chemokine receptor 4. J vis Exp. 2018;133: e57271. https://doi.org/10.3791/57271 .
doi: 10.3791/57271
Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, et al. [
doi: 10.7150/thno.19119
pubmed: 28744319
pmcid: 5525741
Seemann S, Lupp A. Administration of a CXCL12 analog in endotoxemia is associated with anti-inflammatory, anti-oxidative and cytoprotective effects in vivo. PLoS ONE. 2015;10(9): e0138389. https://doi.org/10.1371/journal.pone.0138389 .
doi: 10.1371/journal.pone.0138389
pubmed: 26375818
pmcid: 4574197
Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, et al. Discovery of novel small molecule orally bioavailable C−X−C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010;53(8):3376–88. https://doi.org/10.1021/jm100073m .
doi: 10.1021/jm100073m
pubmed: 20297846
Tamamura H, Araki T, Ueda S, Wang Z, Oishi S, et al. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem. 2005;48:3280–9. https://doi.org/10.1021/jm050009h .
doi: 10.1021/jm050009h
pubmed: 15857134
Tebha SS, Memon SA, Mehmood Q, Mukherjee D, Negida A. Glioblastoma management in low and middle-income countries; existing challenges and policy recommendations. Brain Spine. 2023;3: 101775. https://doi.org/10.1016/j.bas.2023.101775 .
doi: 10.1016/j.bas.2023.101775
pubmed: 38021027
pmcid: 10668069
Thiele S, Mungalpara J, Steen A, Rosenkilde MM, Våbenø J. Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis. Br J Pharmacol. 2014;171(23):5313–29. https://doi.org/10.1111/bph.12842 .
doi: 10.1111/bph.12842
pubmed: 25039237
pmcid: 4294042
Tissue expression of CXCR4. The human protein ATLAS. https://www.proteinatlas.org/ENSG00000121966-CXCR4/tissue
Truax VM, Zhao H, Katzman BM, Prosser AR, Alcaraz AA, et al. Discovery of tetrahydroisoquinoline-based CXCR4 antagonists. ACS Med Chem Lett. 2013;4(11):1025–30. https://doi.org/10.1021/ml400183q .
doi: 10.1021/ml400183q
pubmed: 24936240
pmcid: 4057008
Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13. https://doi.org/10.1016/j.jocn.2018.05.002 .
doi: 10.1016/j.jocn.2018.05.002
pubmed: 29801989
Ueda S, Oishi S, Wang ZX, Araki T, Tamamura H, et al. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J Med Chem. 2007;50:192–8. https://doi.org/10.1021/jm0607350 .
doi: 10.1021/jm0607350
pubmed: 17228861
Vraka C, Dumanic M, Racz T, Pichler F, Philippe C, et al. A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. Nucl Med Biol. 2018;60:29–36. https://doi.org/10.1016/j.nucmedbio.2018.02.002 .
doi: 10.1016/j.nucmedbio.2018.02.002
pubmed: 29529532
Waltenberger M, Furkel J, Röhrich M, Salome P, Debus C, et al. The impact of tumor metabolic activity assessed by
doi: 10.3389/fonc.2022.901390
pubmed: 36203443
pmcid: 9531169
Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171: 105780. https://doi.org/10.1016/j.phrs.2021.105780 .
doi: 10.1016/j.phrs.2021.105780
pubmed: 34302977
pmcid: 8384724
Yang XS, Zhu P, Xie RX, Chen PF, Liu H, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. BMC Cancer. 2023;23(1):1012. https://doi.org/10.1186/s12885-023-11544-4 .
doi: 10.1186/s12885-023-11544-4
pubmed: 37864148
pmcid: 10588198
Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6(7):5022–40. https://doi.org/10.18632/oncotarget.3217 .
doi: 10.18632/oncotarget.3217
pubmed: 25669980
Zimmerman NP, Vongsa RA, Faherty SL, Salzman NH, Dwinell MB. Targeted intestinal epithelial deletion of the chemokine receptor CXCR4 reveals important roles for extracellular-regulated kinase-1/2 in restitution. Lab Invest. 2011;91(7):1040–55. https://doi.org/10.1038/labinvest.2011.77 .
doi: 10.1038/labinvest.2011.77
pubmed: 21537329
pmcid: 3167207